The bill creates the California Foundation for Science and Health Research within the Government Operations Agency to award grants and make loans for scientific and health research and to finance construction of research facilities. It establishes a dedicated state fund that will receive bond proceeds and private donations, requires open scientific exchange and peer review, and limits administrative spending to 3 percent of fund totals.
Why it matters: this is a statewide effort to channel significant public capital into biomedical, environmental, and technology research while linking funding to public‑access expectations for inventions and a stated intent to enable public production of drugs through CalRx. The financing structure and governance rules create new fiscal exposure, procurement preferences, and conflict‑management issues that research institutions, state fiscal officers, and industry will need to navigate.
At a Glance
What It Does
The bill establishes a foundation, a governing council, and a separate finance committee to manage a new research fund and to authorize issuance of state general obligation bonds deposited into that fund. It directs grant and loan awards to California‑based research projects after open scientific peer review and requires IRB approval and public reporting.
Who It Affects
Universities, public and private research institutes, biotech and life‑science firms, state agencies that will oversee projects (e.g., Office of Emergency Services, Natural Resources Agency, Health and Human Services), and the State Treasurer, Controller, and Director of Finance responsible for bond issuance and debt management.
Why It Matters
By pairing grantmaking with state GO bond financing and explicit intent to recoup licensing or enable public production of pharmaceuticals, the bill changes incentives for research commercialization, procurement, and access — and commits the state to multi‑year debt service and new oversight obligations.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill sets up a new entity — the California Foundation for Science and Health Research — housed in the Government Operations Agency. The foundation will run day‑to‑day operations under a director appointed through a process overseen by the Secretary of Government Operations; the secretary also controls compensation for the director.
The foundation’s stated mission covers a broad portfolio: biomedical cures, disease prevention, behavioral health, climate and environmental impacts on health, wildfire prevention, agriculture and water research, and emerging technologies, among others.
Policy decisions about priorities and individual awards rest with a council the bill creates. The council (11–13 members) sets strategic objectives, establishes research priorities, and approves grants and loans by majority vote.
The statute prescribes a mix of scientific experts, public representatives, and ex‑officio or designated seats tied to higher‑education bodies and the California Council on Science and Technology. Members serve four‑year terms, may serve up to two terms, and are unpaid but may be reimbursed for expenses.
The bill authorizes scientific peer review panels and sets conflict‑of‑interest rules that allow certain institutional affiliations while requiring recusal where members have a direct financial interest in a particular award.Funding flows into a newly created California Foundation for Science and Health Research Fund in the State Treasury. The fund can accept private donations and proceeds from bonds and interim borrowing.
All awards must be made to projects located in California (with limited collaborative exceptions), meet IRB and human‑subjects protections, and follow an open, competitive peer review process. The foundation is directed to include terms in awards to recoup a portion of licensing and royalty income; the Legislature also expresses the intent that, in some circumstances, California could publicly produce pharmaceuticals developed with bond funds through CalRx to sell at discounted prices.On the financing side, the bill authorizes issuance of general obligation bonds and creates a finance committee (Treasurer, Controller, Director of Finance, foundation director, and two council designees) to determine bond sales and structure.
The statute contemplates interim debt (PMIA loans, commercial paper, or bond anticipation notes) and allows the Director of Finance to withdraw from the General Fund to seed the program, with repayments required from future bond proceeds. It specifies an interest‑only floating rate structure for interim debt and bonds for at least the initial five years if the committee deems that reduces borrowing costs and minimizes General Fund debt service during the program ramp‑up.
The bill also requires annual public reporting, an independent financial audit with Controller review and public comment, and subjects council meetings to the Bagley‑Keene Open Meeting Act while preserving closed‑session exceptions for privacy, confidential IP, prepublication research, personnel, and security matters.
The Five Things You Need to Know
The bill caps foundation administrative spending at 3 percent of the fund (Section 11899.2(f)).
It authorizes issuance and sale of general obligation bonds up to twenty‑three billion dollars ($23,000,000,000) for the fund (Section 11899.14).
The finance committee may implement an interest‑only, floating‑rate structure for interim debt and bonds for at least the first five full calendar years to defer General Fund debt service during program startup (Section 11899.17(b)).
Council appointments number 11–13 members with most appointees selected by the Secretary of Government Operations and include required seats tied to university systems and the California Council on Science and Technology (Section 11899.3(b)).
The foundation must include grant or loan terms to recoup some licensing and royalty fees from inventions and the Legislature states an intent that California may publicly produce pharmaceuticals developed with bond funds via CalRx under certain circumstances (Section 11899.2(e)).
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Establishes the foundation and defines its mission
This section places the foundation inside the Government Operations Agency, assigns the Secretary of Government Operations responsibility to oversee director appointments and compensation, and lists the broad research fields eligible for funding. Practically, housing the foundation in an existing agency centralizes administrative control and gives the secretary leverage over staffing and budget decisions while the statute leaves day‑to‑day hiring largely to the director once approved by the secretary.
Creates the Fund, eligibility, IP guidance, and procurement preference
This section creates the California Foundation for Science and Health Research Fund and permits both public bond proceeds and private donations. It ties grant eligibility to in‑state projects (with collaborative exceptions), requires IRB approval and open peer review, and instructs the foundation to include terms to recoup licensing or royalty income from bond‑funded inventions. The provision also directs a goal of more than 50 percent of goods and services purchased from California suppliers ‘to the extent reasonably possible,’ which creates a nonbinding procurement preference with compliance and reporting implications.
Sets council composition, terms, voting rules, and conflict provisions
This section creates an 11–13 member council that sets strategic priorities and approves awards. It specifies appointment authorities (primarily the Secretary of Government Operations, plus legislative and institutional designees), term lengths, vacancy timing, and a supermajority safeguard limiting grant approvals when vacancies exceed a threshold. The subsection on conflicts permits council members with institutional or advocacy ties to participate in decisions generally but requires recusal when they have a direct financial interest in a particular award; it also narrows what constitutes a ‘decision’ for purposes of certain conflict statutes.
Peer review and open‑meeting framework with narrow closed‑session exceptions
The statute authorizes scientific peer review panels composed of subject‑matter experts and bars reviewers from having collaborative or commercial relationships with applicants they review. It subjects council and peer review panel meetings to Bagley‑Keene, requires public disclosure and awards in open session, but allows closed sessions for patient privacy, confidential IP and prepublication data, personnel matters, and security concerns. Those carve‑outs are narrowly drawn but will be operationally important where grant proposals include trade secrets or unpublished datasets.
Reporting, audits, and Controller oversight
The foundation must publish an annual report detailing grants, loans, administrative expenses, grantees, and strategic plans, and it must commission an independent annual financial audit. The Controller reviews the audit, issues a public report, and convenes a public meeting with a formal comment period — a built‑in transparency and accountability loop that also creates a recurring administrative workload for Controller staff.
Bond authorization, committee, and repayment mechanics
The act authorizes GO bond issuance for deposit into the fund, continuous appropriation of proceeds for foundation purposes, and establishes the California Foundation for Science and Health Research Finance Committee (Treasurer, Controller, Director of Finance, foundation director, and two council designees) to determine timing and structure of bond sales. It allows successive offerings, refunding bonds, and contemplates interest treatment for federal tax purposes. The committee can direct interim borrowing, and the Director of Finance may withdraw from the General Fund up to the unsold authorized bond amount to seed the fund, with required repayment and interest when bonds are sold.
Interim debt, PMIA loans, bond proceeds use and federal tax technicalities
These provisions authorize interim loans from the Pooled Money Investment Account, permit General Fund withdrawals to support early expenditures, require returns with interest, and allow the Treasurer to maintain segregated accounts if tax‑advantageous bond structures are used. The bill also clarifies that bond proceeds are not ‘proceeds of taxes’ for Prop 4 (Article XIII B) limits, which affects how proceeds are treated in state fiscal accounting.
This bill is one of many.
Codify tracks hundreds of bills on Science across all five countries.
Explore Science in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- California academic researchers and graduate/postdoctoral trainees — gain a new substantial funding source targeted to in‑state projects, plus expanded opportunities for facility construction and collaborative grants. The statute explicitly reserves seats and consideration for graduate‑level and postdoctoral voices on the council, which can increase early‑career visibility.
- Patients and health advocates — stand to benefit from the bill’s express intent to recoup licensing revenue and to make pharmaceuticals developed with bond funds available at discounted prices to Californians, potentially lowering out‑of‑pocket costs for covered drugs.
- California suppliers, manufacturers, and life‑science companies — the >50 percent in‑state procurement goal and bond‑funded capital projects create market opportunities for construction, equipment vendors, and local biotech manufacturing if the foundation enforces those purchasing preferences.
Who Bears the Cost
- California taxpayers/General Fund — GO bonds obligate the state to repay principal and interest; even with interest‑only or interim structures, the state assumes long‑term debt service risk and potential higher costs if markets move against floating‑rate instruments.
- State fiscal officers and agencies (Treasurer, Controller, Director of Finance) — bear operational responsibility for complex debt issuance, interim loan management, segregated accounts for tax compliance, and public audit processes; these functions require staff time and may increase workload without an explicit funding stream.
- Grantees and private partners — will face award conditions (open access, IRB compliance, potential royalty sharing or state production clauses) that change commercialization pathways and may reduce exclusive licensing leverage for some recipients, affecting revenue expectations.
Key Issues
The Core Tension
The central tension is between using large public borrowing to accelerate research and ensure public‑interest outcomes (open science, discounted drugs, public manufacture) and preserving the commercial incentives and contractual certainty that attract private partners and sustain long‑term technology transfer — all while managing substantial fiscal risk to the state if borrowing costs rise or program cash flows differ from projections.
The bill mixes two strong objectives — ramping up state investment in high‑priority research and maximizing public benefit from that investment — but leaves open how those objectives will be balanced in practice. The mandate to recoup licensing revenue and the stated intent to enable CalRx production do not set clear thresholds or conditions for when California will exercise public manufacture, nor do they specify how royalty recoupment will affect grantee‑level IP agreements or existing university tech‑transfer practices.
Those gaps could create disputes between the foundation, universities, and industry partners over ownership, pricing, and manufacturing rights.
On the financing side, the $23 billion authorization and the permitted use of interest‑only, floating‑rate interim debt for at least five years shift near‑term debt service off the General Fund but can increase overall borrowing cost and exposure to market‑rate volatility. The bill authorizes General Fund withdrawals and PMIA loans to seed the program, but repayment timing and reliance on future bond markets introduce fiscal risk.
Operationally, the 3 percent administrative cap is tight for a new statewide grantmaker that must run competitive peer review, compliance monitoring, procurement, and audits. Finally, the bill contains blank placeholders for certain dollar amounts in Sections 11899.11 and 11899.12 — a drafting gap that will need resolution before implementation and that currently obscures the intended split between facility construction funds and other program funds.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.